Versartis Inc (VSAR)

20.50
0.35 1.74
NASDAQ : Health Care
Prev Close 20.15
Open 20.20
Day Low/High 19.60 / 20.65
52 Wk Low/High 6.17 / 19.76
Volume 259.04K
Avg Volume 242.10K
Exchange NASDAQ
Shares Outstanding 35.05M
Market Cap 690.41M
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Twitter Is One of Five Stocks Insiders Really Love Right Now

Twitter Is One of Five Stocks Insiders Really Love Right Now

Insiders at these companies have been scooping up shares in their own organizations lately.

Versartis' Pipeline Holds Big Promise

Versartis' Pipeline Holds Big Promise

This small-cap biotech name could have further to run.

Versartis' Pipeline Holds Big Promise

Versartis' Pipeline Holds Big Promise

This small-cap biotech name could have further to run.

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.

Commit To Buy Versartis At $10, Earn 46.5% Annualized Using Options

Commit To Buy Versartis At $10, Earn 46.5% Annualized Using Options

Investors eyeing a purchase of Versartis Inc stock, but cautious about paying the going market price of $12.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $10 strike, which has a bid at the time of this writing of $1.35.

Versartis Presents Safety, Efficacy And IGF-I Data For Somavaratan In Pediatric Growth Hormone Deficiency At The 2016 Congress Of The GRS & IGF Society

Versartis Presents Safety, Efficacy And IGF-I Data For Somavaratan In Pediatric Growth Hormone Deficiency At The 2016 Congress Of The GRS & IGF Society

Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and height velocity from year 1 to year 2

Versartis Enters Oversold Territory (VSAR)

Versartis Enters Oversold Territory (VSAR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Shark Bites: Versartis Is a Biotech Worth Tracking

Shark Bites: Versartis Is a Biotech Worth Tracking

Biotechnology stocks can be risky but it's helpful to track them over time.

Short Interest Decreases By 26.6% For VSAR

Short Interest Decreases By 26.6% For VSAR

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 352,820 share decrease in total short interest for Versartis Inc , to 974,210, a decrease of 26.59% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Versartis Announces Completion Of Enrollment In Phase 3 VELOCITY Trial Of Somavaratan In Pediatric GHD

Versartis Announces Completion Of Enrollment In Phase 3 VELOCITY Trial Of Somavaratan In Pediatric GHD

Total of 137 patients enrolled; top-line results expected in Q3 2017

Versartis Reports Second Quarter 2016 Financial Results

Versartis Reports Second Quarter 2016 Financial Results

Enrollment to be Complete by Mid-August in the Phase 3 VELOCITY Trial for Pediatric GHD; Data Expected Q3 2017

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.